A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Celgene
Study ID
NCT03930953
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CC-99282 — DRUG
    Specified dose on specified days
  • Rituximab — DRUG
    Specified dose on specified days
  • Obinutuzumab — DRUG
    Specified dose on specified days
  • Tafasitamab — DRUG
    Specified dose on specified days
  • Valemetostat — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.

Key Dates

Start date
May 20, 2019
Status verified
Feb 2026
Primary completion
Apr 7, 2027
Completion
Feb 9, 2028

Study Design

Enrollment
438 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A: Dose Escalation
  • Experimental: Part B: Dose Expansion

Primary Outcome Measure

Incidence of Adverse Events (AEs) [ Time Frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years) ]

Locations (8)

FacilityCityStateZIPSite coordinators
Local Institution - 109ScottsdaleArizona85259-
Local Institution - 111JacksonvilleFlorida32224-
Local Institution - 102TampaFlorida32207-
Local Institution - 108Overland ParkKansas66210-
Local Institution - 107RochesterMinnesota55905-
Local Institution - 104St LouisMissouri63110-
Local Institution - 103HackensackNew Jersey07601-
Local Institution - 101HoustonTexas77030-

Find similar trials in Scottsdale, AZ

Related Studies